Cyteir is currently conducting a Phase 1/2 study of CYT-0851 in B-Cell malignancies and advanced solid tumors. CYT-0851 is an orally delivered investigational drug that is designed to inhibit the protein RAD51. Certain malignancies rely heavily on a DNA damage repair process that involves RAD51. By inhibiting RAD51’s role in DNA damage repair, CYT-0851 seeks to force tumor cells into a cell-death pathway as a means for treating the patient’s disease.
More information on the trial and enrolling sites can be found at www.clinicaltrials.gov.